ES2113372T3 - Utilizacion de un anticoagulante como agente de diagnostico. - Google Patents

Utilizacion de un anticoagulante como agente de diagnostico.

Info

Publication number
ES2113372T3
ES2113372T3 ES91902118T ES91902118T ES2113372T3 ES 2113372 T3 ES2113372 T3 ES 2113372T3 ES 91902118 T ES91902118 T ES 91902118T ES 91902118 T ES91902118 T ES 91902118T ES 2113372 T3 ES2113372 T3 ES 2113372T3
Authority
ES
Spain
Prior art keywords
anticoagulant
esp
new
diagnostic agent
compsns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902118T
Other languages
English (en)
Inventor
Christiaan Reutelingsperger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6396455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2113372(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2113372T3 publication Critical patent/ES2113372T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Dental Preparations (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)

Abstract

EL OBJETO DE LA PRESENTE INVENCION SON AGENTES, ESPECIALMENTE ANEXINAS, QUE ESTAN MARCADAS CON UNA SUSTANCIA DETECTABLE ASI COMO SU EMPLEO PARA EL DIAGNOSTICO.
ES91902118T 1989-12-27 1990-12-19 Utilizacion de un anticoagulante como agente de diagnostico. Expired - Lifetime ES2113372T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3942988 1989-12-27

Publications (1)

Publication Number Publication Date
ES2113372T3 true ES2113372T3 (es) 1998-05-01

Family

ID=6396455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902118T Expired - Lifetime ES2113372T3 (es) 1989-12-27 1990-12-19 Utilizacion de un anticoagulante como agente de diagnostico.

Country Status (15)

Country Link
EP (2) EP0509026B1 (es)
JP (1) JP3135261B2 (es)
KR (1) KR0181520B1 (es)
AT (2) ATE429644T1 (es)
AU (1) AU642202B2 (es)
CA (1) CA2070647C (es)
DE (3) DE59010815D1 (es)
ES (1) ES2113372T3 (es)
FI (1) FI107586B (es)
HU (2) HU209650B (es)
NO (1) NO305276B1 (es)
NZ (1) NZ236620A (es)
PT (1) PT96385B (es)
WO (1) WO1991009628A1 (es)
ZA (1) ZA9010319B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
EP1138334A3 (en) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
WO1995014788A1 (en) * 1993-11-24 1995-06-01 University Of Washington Blood coagulation retardants and devices
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
JP3664727B2 (ja) * 1994-01-24 2005-06-29 ネオルクス コーポレイション 放射標識したアネキシン
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
EP0763056B1 (en) * 1994-03-16 2000-08-09 Mallinckrodt Inc. Use of surfactants for stabilization of peptides and proteins for radiopharmaceutical use
US5834196A (en) * 1994-04-11 1998-11-10 Nexins Research B.V. Method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
CA2185349C (en) * 1994-06-16 2010-04-20 John M. Reno Radiolabeled annexin-galactose conjugates
WO1995034315A1 (en) * 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
WO1996017618A1 (en) * 1994-12-07 1996-06-13 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
JPH10512852A (ja) * 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
FR2736197B1 (fr) * 1995-06-29 1997-09-12 Univ Paris Curie Nanoparticules magnetiques couplees a de l'annexine et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
DE3810331A1 (de) * 1988-03-26 1989-10-05 Boehringer Ingelheim Int Monoklonale vac-antikoerper

Also Published As

Publication number Publication date
NO922528L (no) 1992-08-26
CA2070647A1 (en) 1991-06-28
AU642202B2 (en) 1993-10-14
DE4040817A1 (de) 1991-07-04
JPH05502877A (ja) 1993-05-20
DE59010946D1 (de) 2009-06-04
JP3135261B2 (ja) 2001-02-13
HU9202149D0 (en) 1992-10-28
NO305276B1 (no) 1999-05-03
KR920703121A (ko) 1992-12-17
FI107586B (fi) 2001-09-14
EP0509026A1 (de) 1992-10-21
EP0806670B1 (de) 2009-04-22
AU7071191A (en) 1991-07-24
PT96385A (pt) 1991-10-31
HUT61491A (en) 1993-01-28
FI922719A0 (fi) 1992-06-12
CA2070647C (en) 2001-04-10
ATE429644T1 (de) 2009-05-15
ZA9010319B (en) 1992-08-26
NZ236620A (en) 1997-03-24
EP0509026B1 (de) 1998-03-18
EP0806670A2 (de) 1997-11-12
HU209650B (en) 1994-09-28
ATE164083T1 (de) 1998-04-15
EP0806670A3 (de) 1997-12-10
NO922528D0 (no) 1992-06-26
KR0181520B1 (ko) 1999-05-01
PT96385B (pt) 1998-06-30
DE59010815D1 (de) 1998-04-23
WO1991009628A1 (de) 1991-07-11

Similar Documents

Publication Publication Date Title
ES2113372T3 (es) Utilizacion de un anticoagulante como agente de diagnostico.
SE8000469L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
ES2113532T3 (es) Dispositivo para la determinacion del nivel de llenado de un sistema circulatorio sanguineo.
DE69734060D1 (de) Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
ATE123301T1 (de) Gentechnologisch-hergestellte aprotinin-homologe.
FI963802A0 (fi) Trombolyyttisesti aktiivisten proteiinien ja antikoagulanttien yhdistelmiä ja niiden käyttöjä
SE9103332L (sv) Metod foer diagnos av blodkoagulationssjukdomar
Stefanini et al. Platelets: VII. Shortened “Platelet Survival Time” and Development of Platelet Agglutinins Following Multiple Platelet Transfusions.
BR9306344A (pt) Antigeno hb15 de ativação de linfócito um membro da super família das imunoglobulinas
DE59008813D1 (de) Mittel zur neutralisierung der tumorzellen-assoziierten prokoagulant-aktivität.
DK0655089T3 (da) Virkninger af actinfilamenter på fibrinkoagulatstruktur og -lyse
FI913818A0 (fi) Nytt trombolytiskt aemne.
SE8404283D0 (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
DK226889D0 (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
ES2078289T3 (es) Agente para mejorar la recuperacion de anexinas.
DE69001686D1 (de) Behandlung von leukozytstoerungen mit gm-csf.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
Magee et al. The liver as a site for interferon production in response to poly I: poly C
Al-Mondhiry et al. Platelet and fibrinogen survival in calves implanted with artificial heart and ventricular assist device-correlation with autopsy findings
Ramrakhyani et al. Hepatitis B viral markers and liver disease in haemophiliacs: A study in an Indian population
El Ouarzazi et al. Intramedullary tuberculosis. Surgical treatment. Les tuberculoses intramedullaires traitement medico-chirurgical.
TAKETOMI et al. The ultrastructural localization of platelet factor 4 and fibronectin in human platelets
DE69131248D1 (de) Inhibition der ausscheidung von natrium durch die na-k-atpase
Yacoub et al. Intra-arterial Perfusion of Pancreatic Juice in the Hind Limb of Dogs: Effects on the Peripheral Vascular Resistance

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 509026

Country of ref document: ES